Clinical trial · Interventional
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
NCT00526305CI-TRIAL-00002962completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytosine Arabinoside | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Hydrocortisone | Drug | — | UNRESOLVED |
| L-Asparaginase | Drug | Asparaginase | ALIAS |
| Mercaptopurine | Drug | Mercaptopurine | ALIAS |
| Mitoxantrone | Drug | Mitoxantrone | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the efficacy of treatment in order to response rate, relapse free survival and overall survival
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: ALL BCR/ABL+ patients Age \< 65 years No previous treatment Exclusion Criteria: 1. Other LLA variability 2. Previous history of coronary valvular, hypertensive cardiopathy illness 3. Chronic hepatic illness 4. Chronic respiratory insufficiency 5. Renal insufficiency not caused by LLA 6. Severe neurological problems not caused by LLA 7. Severe affection of the performance status (grade 3-4 OMS gradation) not caused by LLA
References
Publications (0)
Data not yet available
No reference posted for this study.